<?xml version="1.0" encoding="UTF-8"?>
<p id="para0027">IFNα is a member of the family of type I IFNs that plays an important role in host resistance to viral infection. IFNα suppresses viral infection by directly interfering with replication of the virus and by promoting both innate and adaptive immune responses. In vitro experiments showed that IFNα effectively inhibits the replication of SARS-CoV 
 <xref rid="bib0064" ref-type="bibr">[64</xref>,
 <xref rid="bib0065" ref-type="bibr">65]</xref>. It has also been reported that cynomolgus monkeys are protected from infection with SARS CoV by treatment with IFNα 
 <xref rid="bib0066" ref-type="bibr">[66]</xref>. Moreover, the therapeutic benefit of synthetic recombinant IFNα for patients with SARS was demonstrated in a pilot clinical trial 
 <xref rid="bib0067" ref-type="bibr">[67]</xref>. Thus, IFNα should be considered a candidate drug for COVID-19 therapy.
</p>
